Discovery and Validation of New Potential Biomarkers for Early Detection of Colon Cancer

• Xavier Solé ,

  Contributed equally to this work with: Xavier Solé, Marta Crous-Bou, David Cordero

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Marta Crous-Bou ,

  Contributed equally to this work with: Xavier Solé, Marta Crous-Bou, David Cordero

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• David Cordero ,

  Contributed equally to this work with: Xavier Solé, Marta Crous-Bou, David Cordero

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• David Olivares,

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Elisabet Guinó,

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Rebeca Sanz-Pamplona,

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Francisco Rodriguez-Moranta,

  Affiliations Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, Department of Gastroenterology, University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Xavier Sanjuan,

  Affiliations Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, Department of Pathology, University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Javier de Oca,

  Affiliations Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, Department of Clinical Sciences, Faculty of Medicine, University of Barcelona (UB), Barcelona, Spain, Department of General and Digestive Surgery, Colorectal Unit, University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Ramon Salazar,

  Affiliations Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Victor Moreno

  * E-mail: v.moreno@iconcologia.net

  Affiliations Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain, Department of Clinical Sciences, Faculty of Medicine, University of Barcelona (UB), Barcelona, Spain

  ⨯